XTRA:SY1Chemicals
Large Non‑Cash Impairments And Portfolio Moves Might Change The Case For Investing In Symrise (XTRA:SY1)
Symrise AG has recorded non-cash impairment charges of about €145 million on its terpenes business and €150 million on its investment in Swedencare AB, both booked in the fourth quarter of 2025 and linked to a planned sale process and application of IFRS 5.
The company also plans to present at the 25th German Corporate Conference in Frankfurt, giving management an opportunity to explain how these impairments and portfolio moves affect its financial profile and business focus.
Next, we’ll...